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Abstract
A decade on from the description of JAK2 V617F, the MPNs are circumscribed by an increasingly intricate landscape. There is now evidence
that they are likely the result of combined genetic dysregulation, with several mutated genes involved in the regulation of epigenetic mecha-
nisms. Epigenetic changes are not due to a change in the DNA sequence but are reversible modifications that dictate the way in which genes
may be expressed (or silenced). Among the epigenetic mechanisms, DNA methylation is probably the best described. Currently known MPN-
associated mutations now include JAK2, MPL, LNK, CBL, CALR, TET2, ASXL1, IDH1, IDH2, IKZF1 and EZH2. Enhancing our knowledge about
the mutation profile of patients may allow them to be stratified into risk groups which would aid clinical decision making. Ongoing work will
answer whether the use of epigenetic therapies as alterative pathway targets in combination with JAK inhibitors may be more effective than sin-
gle agent treatment.
Keywords: myeloproliferative neoplasm epigenetics cell signalling janus kinase DNA methylation histone
modificationmiRNA regulation combination epigenetic therapy
Introduction
Genomic instability is fundamental to the development of cancers [1].
The myeloproliferative neoplasms (MPNs) arise when acquired muta-
tions in haematopoietic stem cells cause a change from the polyclonal
haematopoiesis seen in health to an abnormal monoclonal haemato-
poiesis [2]. The classic BCR/ABL-negative MPNs include poly-
cythaemia vera (PV), essential thrombocythaemia (ET) and primary
myelofibrosis (PMF). They are defined, respectively, by the excess
production of erythrocytes, platelets and bone marrow fibrosis. The
MPN symptom burden is heterogeneous, ranging from patients who
are relatively asymptomatic to those suffering with severe constitu-
tional symptoms, thrombotic disease or transformation to secondary
acute myeloid leukaemia (AML). Transformation to AML is the most
devastating complication experienced by MPN patients, seen in 20%
of PMF, 4.5% in PV and 1% in ET [2–5]. It is usually refractory to
treatment and in the majority of cases patients ultimately die of their
disease. Therefore, early predictors of leukaemic risk are hugely
important [6]. A single-point mutation in the tyrosine kinase JAK2 is
present in the majority of patients and has become part of the formal
diagnostic criteria for these conditions [7–10]. However, it is not pre-
sent in every case and does not explain the phenotypic differences
between these three diseases and even between patients. A decade
on from the description of JAK2 V617F, the MPNs are circumscribed
by an increasingly intricate landscape [11]. The influence of molecular
abnormalities beyond the JAK/STAT pathway is ever more being
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scrutinised. There is now evidence that the MPNs are likely the result
of combined genetic dysregulation with several mutated genes
involved in the regulation of epigenetic mechanisms. They appear to
be the most frequent after JAK2 V617F and CALR mutations. In this
review, we explore the evidence for epigenetic dysregulation in the
MPNs, where recent advances may be helpful in the need for risk-
adapted therapeutic stratification.
Mutations affecting cell signalling
Normal haematopoiesis is regulated mainly by cytokines such as ery-
thropoietin (EPO), granulocyte colony-stimulating factor (GCSF) and
thrombopoietin (TPO). These cytokines stimulate receptors on the
surface of cells and activate the associated Janus kinase (JAK). This
protein autophosphorylates and binds to a STAT (signal transducer
and activator of transcription) protein, which is in turn itself phospho-
rylated. The STAT protein then dimerizes and translocates into the
nucleus of the cell. Here, it binds to DNA at a promoter site and
causes gene transcription (Fig. 1: JAK/STAT pathway). STAT proteins
affect basic cell functions such as cell growth, differentiation and
apoptosis.
The point mutation JAK2 V617F was initially described in 2005 [2,
12–15], located in exon 14 of the gene, and it results in a single base
change from guanine to thymine at nucleotide position 1849, leading
to an amino acid change from valine to phenylalanine at codon 617.
This leads to constitutively active JAK2 kinase signalling that is inde-
pendent of cytokine stimuli. Approximately 95% PV patients, 50–70%
ET patients and 40–50% PMF patients possess the JAK mutation [2,
16]. However, initial excitement was short-lived when it became clear
that its role in MPNs was not as pathognomonic as BCR/ABL in
chronic myeloid leukaemia (CML) [1]. JAK2 V617F positivity or high
mutant allele burden does not seem to have a clear association with
survival, leukaemia transformation or risk of thrombosis [17]. In
recent years, several other mutations in this pathway have been
described. A second mutation in JAK2 can occur at exon 12 with simi-
lar functional consequences to the canonical mutation [2, 18]. It
occurs in a small percentage of JAK2 V617F-negative PV patients, but
not in ET or PMF. The myeloproliferative leukaemia virus oncogene
(MPL) encodes the receptor for TPO via JAK-STAT signalling.
Somatic mutations affecting exon 10 of MPL are seen in up to 15% of
JAK2 V617F-negative ET and MF patients [2, 19, 20]. This gain-of-
function mutation is due to a substitution of tryptophan to leucine at
codon 515 and leads to constitutive phosphorylation of JAK2, STAT3,
STAT5, ERK and AKT proteins [21–23]. Lymphocyte-specific adaptor
protein (LNK) negatively regulates TPO/EPO signalling, and a loss-of-
function mutation is found here at low frequency in JAK2-negative
patients [24, 25]. Further downstream, mutations in suppressors of
cytokine signalling (SOCS) and Casitas B cell lymphoma (CBL) have
been seen rarely in within MPN patients. In 2013, a mutation in exon
9 of the calreticulin (CALR) gene was identified, by next-generation
sequencing (NGS), in approximately 73% of JAK2/MPL-negative ET
and MF patients [26, 27]. CALR is present in the endoplasmic reticu-
lum, where it forms a key component of the quality-control machinery
that ensures proper glycoprotein folding and it also contributes to cal-
cium homeostasis. Recent work has demonstrated the exact mecha-
nism by which CALR causes the MPN phenotype, where the mutant
proteins interact with the thrombopoietin receptor (MPL) and directly
lead to dimerization and activation of JAK2 [28–30]. Retrospective
analysis of clinical data suggests that CALR-positive patients have a
more benign clinical course than patients with the same MPN who
are JAK2 or MPL positive [26]. Compared to JAK2 patients, CALR
patients have a lower risk of thrombosis and longer overall survival
(OS) [26]. Identification of these additional mutations means that up
to 95% of patients can now be reliably diagnosed (Fig. 2: Frequency
of MPN-specific mutations).
Mutations in epigenetic-associated
genes
In a study using targeted NGS of 104 cancer-related genes on 197
MPN patients to examine clonal evolution over time [31], approxi-
mately 10% of patients had no mutation detectable in any of the
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Fig. 1 JAK/STAT pathway. A cytokine
stimulates the cell surface receptor and
activates the associated Janus kinase
(JAK). This protein autophosphorylates
and binds to a STAT (signal transducer
and activator of transcription) protein,
which is in turn itself is phosphorylated.
The STAT protein then dimerizes and
translocates into the nucleus of the cell.
Here, it binds to DNA at a promoter site
and causes gene transcription.
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genes analysed and 54% had mutations only in JAK2 V617F or CALR.
These patients were found to have the most favourable prognosis and
the lowest risk of disease progression. The remaining 36% had addi-
tional mutations detected, other than JAK2 V617F or CALR. Most of
these were mutations affecting genes implicated in epigenetic regula-
tion (TET2 12%, ASXL1 5%, DNMT3a 5%, EZH2 ~3% and IDH1
~1.5%) [31]. Many mutations in epigenetic-associated genes are not
exclusive to MPN and are seen in a wide spectrum of myeloid malig-
nancies. They can also coexist with JAK2/CALR/MPL suggesting that
in some cases, these two classes of mutations may combine together
produce the individual MPN phenotype. It is thought that the rate of
clonal evolution in MPN is slow and most mutations are already pre-
sent at diagnosis. However, the order in which mutations are acquired
may also affect disease phenotype. Of note, the reversible nature of
epigenetic changes may make them good potential therapeutic tar-
gets.
Epigenetic changes are not due to a change in the DNA sequence
but are reversible modifications that dictate the way in which genes
may be expressed (or silenced). It can do this through alterations in
DNA methylation, modification of histones or chromatin structure, or
via changes to RNA.
To understand these epigenetic changes, it is essential to under-
stand the structures that aid the packaging of DNA within the cell
nucleus (Fig. 3: The nucleosome). The nucleosome consists of a core
of eight histone proteins (two of histone H2A, H2B, H3 and H4)
around which DNA is tightly coiled. This structure is further stabilized
by histone H1. DNA is negatively charged, while lysine residues on
histones hold a positive charge. The nucleosome is not static and
changes in the condensed nature of chromatin signal for changes in
gene transcription.
JAK2
In addition to its prominent role in cytokine signalling, mutant JAK2
may have an epigenetic role through its presence in the nucleus
where it can lead to phosphorylation of histone H3 and the arginine
methyltransferase PRMT5 [32, 33] (Fig. 4: The epigenetic effects of
JAK2). Phosphorylation of H3 at position Y41 blocks the binding of
heterochromatin protein 1a leading to changes in gene transcription,
DNA repair and other cellular processes [21]. Phosphorylation of
PRMT5 prevents its association with methylosome protein 50
(MEP50), leading to decreased methylation of histones H2A and H4.
DNA methylation
Among the epigenetic mechanisms, DNA methylation is probably the
best described. The addition of methyl groups to DNA typically occurs
predominately at CpG sites (cytosine and guanine separated by one
phosphate in the linear sequence of bases along the length of the
DNA) prior to the promoter regions of genes [34, 35]. Cytosines are
methylated by the addition of a methyl group to the five carbon ring
of the pyrimidine ring under the action of DNA methyltransferase
(DNMT) enzymes; the 5-methylcytosine (5-mc) formed acts to
repress gene transcription. The methyl group (CH3) is donated by S-
adenosyl methionine (SAM), which itself is reduced to S-adenosyl
homocysteine (SAH). Conversely, the ten-eleven translocation (TET)
proteins belong to a family of alpha-oxaloglutarate-dependent
enzymes which catalyse the conversion of 5-mc to 5-hydroxymethyl-
cytosine (5-hmc), an initial step in demethylating DNA that ultimately
leads back to an upregulation of transcription. Isocitrate dehydroge-
nase (IDH) enzymes catalyse the conversion of isocitrate to a-keto-
glutarate, a reaction that is required for the function of TET enzymes.
These mechanisms (Fig. 5: Overview of DNA methylation) help to
regulate gene expression in normal development. In the development
of cancer, a gain of methylation in a tumour suppressor gene would
lead to gene inactivation and a loss of methylation in proto-oncogenic
genes would lead to gene expression [36].
Mutations of TET2 impair the function of TET enzymes, resulting
in reduced levels of 5-hmc. As discussed above, they are seen in 16%
PV, 5% ET and 17% PMF [37]. They also occur in mastocytosis,
AML, myelodysplastic syndromes (MDS) and more than half of
chronic myelomonocytic leukaemia (CMML) cases [37, 38]. Murine
models with TET2 mutations had an expansion of the haematopoietic
stem cell compartment and in particular demonstrated myelomono-
cytic proliferation [39]. In one study of MPN patients by Lundberg
et al., TET2 mutations were seen to confer a high risk of leukaemic
transformation (increased by 30%) and shorter OS [31]. In addition,
there is evidence that TET2 mutations appear to be an early event that
may provide clonal advantage and set up a ‘fertile ground’ for MPN
disease initiation [40, 41].
DNMT 3A and 3B (alpha and beta) carry out de novo methylation
while DNTM1 maintains existing methylation patterns after cell divi-
sion. Mutations in DNMT3A were initially found in AML patients and
confer an intermediate to adverse prognosis. They have been seen
less frequently in MPN, in approximately 10% of patients [2]. They
may cause a gain or loss of function. The most common mutation
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Fig. 2 Frequency of MPN-specific muta-
tions. JAK2 V617F Janus kinase 2, valine
to phenylalanine at codon 617. CALR Cal-
reticulin. MPL Myeloproliferative leukae-
mia virus oncogene. Exon 12 Janus
kinase exon 12. LNK Lymphocyte-specific
adaptor protein. CBL Casitas B cell
lymphoma.
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R882H causes a loss of function and the consequently reduced
methylation acts to increase gene transcription with murine models
displaying myeloid proliferation with thrombocytosis. Initially,
DNMT3A mutations were only reported early in myeloid disease, prior
to gaining JAK2 [42]. However, it seems that these mutations can
also be acquired late in disease development and the order of acquisi-
tion may be associated with differences in MPN phenotype [42].
When they occur prior to JAK2, they are associated with ET, whereas
the reverse is associated with PV. However, studies to date have not
clearly linked DNMT mutations with clinical outcome in MPN patients.
The enzymes IDH 1 and 2 (IDH1/2) map to chromosomes 2 and
15, respectively. IDH1/2 mutations were first described in 2008 in
gliomas and occur at low frequency in MPN. The largest study of IDH
mutations in MPN reported frequencies of approximately 2% in PV,
1% ET, 4% PMF and 22% in blast phase MPN [43]. In blast phase,
MPN IDH mutational status predicted poor prognosis.
Most DNA methylation studies in MPN have been carried out
looking at single-gene mutations, but one study has looked at the
epigenetic landscape by examining global DNA methylation in 71
chronic PV/ET/PMF patients [36]. An aberrant methylation pattern
was seen in these patients when compared to healthy controls,
but no difference was seen between the three MPN phenotypes.
However, in 13 of patients samples taken during transformation
to secondary AML were also examined and these had an
increased number of differentially methylated regions when com-
pared to the samples from chronic patients [36]. Interestingly,
analysis of the enriched genes indicated they were involved in
important signal transduction pathways such as NFkB (nuclear
factor kappa light-chain enhancer of activated B cells) and binding
sites for important transcription pathways such as globin tran-
scription factor 1 (GATA1). GATA1 has critical functions in ery-
throcyte development including establishment of the cytoskeleton
and polypeptide globin chains. In patients who transformed to
AML, genes in the interferon (IFN) pathway were seen to be
hypermethylated, which may be important given IFN has a role in
tumour surveillance.
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Fig. 3 The nucleosome. This structure
consists of a core of eight histone pro-
teins (two of histone H2A, H2B, H3 and
H4) around which DNA is tightly coiled.
It is further stabilized histone H1.
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Fig. 4 The epigenetic effects of JAK2.
Mutant JAK2 may have an epigenetic role
through its presence in the nucleus where
it can lead to phosphorylation of histone
H3 and the arginine methyltransferase
PRMT5. Phosphorylation of H3 at position
Y41 blocks the binding of heterochromatin
protein 1a (HP1a), and phosphorylation
of PRMT5 prevents its association with
methylosome protein 50 (MEP50).
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Histone modifications and regulation
of chromatin structure
The N terminal lysine residues on histones are prone to post transla-
tional modification, leading to transcriptional activation or repression.
These covalent modifications can include acetylation, methylation and
phosphorylation, among others. Acetylation occurs at lysine (K) resi-
dues particularly on histone H3 and H4. Histone acetyl transferases
are enzymes that aid the transfer of acetyl groups, while histone
deacetylases (HDACs) remove acetyl residues from histone tails. Dis-
ruption of this equilibrium can play a role in the development of can-
cer and have been described in AML. The methylation of histones
takes place on lysine, arginine and histidine residues. An additional
layer of complexity is added as lysines may be mono- (me), di- (me2)
or tri- (me3) methylated. As with DNA, SAM donates the methyl
group under the action of histone methyltransferase (HMT) enzymes.
Certain commonly studied histone methylation marks are in general
associated with transcription activation (H3K4: histone H3 at lysine
(K) amino acid 4) while others are associated with transcriptional
repression (H3K9).
Yet little is known about the role of individual histone modifica-
tions within MPNs, and current research has focused mainly on
changes relating to the polycomb group proteins. These are a family
of proteins which can remodel chromatin thus exerting a repressive
effect on gene expression. Polycomb repressive complex 2 (PRC2)
catalyses di- and trimethylation of lysine 27 on histone H3
(H3K27me2/3), leading to gene silencing. Addition of sex combs like
protein 1 (ASXL1) maps to chromosome 20 and is thought to be an
important mediator of PRC2 function [44]. Mutations in ASXL1 were
first described in 2009 in MDS/AML [45]. Studies of the effect of
ASXL1 mutations in MDS patients demonstrated that they predicted
for worse outcome [46]. In murine models, loss of asxl1 resulted in
progressive multilineage cytopenias and dysplasia [47]. Deletions,
insertions and nonsense mutations of ASXL1 have been found in 3%
ET and 13% PMF [37]. Among patients with MPNs, ASXL1 mutations
appear to be commoner in older patients as well as in patients with
PMF or post-ET/PV MF. In PMF, they are associated with a more sev-
ere anaemia and the inferior survival of patients [48].
EZH2 (enhancer of zeste homolog 2) is another key regulator of
PRC2 [49]. EZH2 is present on chromosome 7 and is overexpressed
in solid tumours such as lymphoma. MPN-associated EZH2 muta-
tions result in a loss of function and may have tumour suppressor
activity [37]. Both EZH2 and ASXL1 are thought to occur later in MPN
development, but to date, there is no definite evidence that they carry
any independent prognostic value.
miRNA regulation
Changes in the regulation of RNA can lead to cell cycle arrest and
apoptosis. Described mutations here include SF3B1, SRSF2 and
IKZF1 (IKAROS family zinc finger 1). SF3B1 mutations are seen most
often in a subtype of MDS (RARS—refractory anaemia with ring
sideroblasts), while SRSF2 is seen in CMML. They can also occur at
low frequency in MPN patients (around 5%) with the suggestion that
SRSF2 confers poor prognosis in MF. IKZF1 deletions are rare in
chronic phase MPN but have been detected at transformation to AML.
They have been previously described mainly in lymphoid diseases
and are believed to modulate expression of lineage-specific genes
[17].
JAK inhibition and potential for
combination with epigenetic therapies
Disease complications are a leading cause of morbidity and mortality
in MPN patients and play an important role in determining when to
DNMT
Cytosine 5-mc 5-hmc
TET
SAM SAH
IDH
Isocitrate α-ketoglutarate
Unmethylated
Open chromatin structure
Active transcription
Methylated
Closed chromatin structure
Transcription impeded
Fig. 5 Overview of DNA methylation. Cytosines are methylated by the addition of a methyl group to the 5 carbon ring of the pyrimidine ring under
the action of DNA methyltransferase (DNMT) enzymes; the 5-methylcytosine (5-mc) formed acts to repress gene transcription. The methyl group
(CH3) is donated by S-adenosyl methionine (SAM), which itself is reduced to S-adenosyl homocysteine (SAH). Conversely, the ten-eleven transloca-
tion (TET) proteins belong to a family of alpha-oxaloglutarate dependent enzymes which catalyse the conversion of 5-mc to 5-hydroxymethylcytosine
(5-hmc), an initial step in demethylating DNA that ultimately leads back to an upregulation of transcription. Isocitrate dehydrogenase (IDH) enzymes
catalyse the conversion of isocitrate to a-ketoglutarate, a reaction that is required for the function of TET enzymes.
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initiate treatment [40]. Current prognostic scoring systems for ET and
PV do not take into account any genetic markers and are based solely
on patient age, blood counts and development of complications. Stan-
dard treatments for the classic BCR/ABL-negative MPNs include low-
dose aspirin, cytotoxic drugs such as hydroxycarbamide or anagre-
lide, venesection and IFN. In younger patients with high-risk MF or
transformation to secondary AML, intensive chemotherapy followed
by bone marrow transplantation may be considered. In 2011, the
JAK1/2 inhibitor ruxolitinib (also known as INCB18424) was approved
for the treatment of intermediate-risk and high-risk myelofibrosis. In
clinical trials, when it was compared to the best available therapy
(BAT), ruxolitinib resulted in a rapid reduction in spleen size (35% or
more from baseline by MRI or CT) and also improved constitutional
symptoms (including anorexia, shortness of breath, fatigue, insomnia
and pain) leading to improved quality of life [50]. In a subsequent 3-
year follow-up study (COMFORT-II), longer overall survival (OS) was
also seen in patients on continuous ruxolitinib [51]. This medication
is now being trialled in PV and ET. ‘RESPONSE’ evaluated the safety
and efficacy of ruxolitinib in 110 PV patients, compared to BAT. Rux-
olitinib was superior in controlling haematocrit, reducing spleen vol-
ume and improving symptoms such as sweats, itch, lethargy and
abdominal discomfort [52]. Preliminary reports from the investigator
lead study ‘MAJIC’ suggest that for the treatment of ET, ruxolitinib
offered no advantage in terms of complete haematological remission
rates, compared to BAT. However, once again benefits were seen for
constitutional symptoms with patients reporting improvement in pru-
ritus, weight loss and early satiety [53]. Despite clear clinical benefits,
treatment with ruxolitinib does not seem to reduce mutant allele bur-
den, neither in patients nor in mouse models [54]. This is in contrast
to the effect of the tyrosine kinase inhibitors on BCR/ABL in CML and
has caused researchers to question whether JAK2 is an essential
therapeutic target in MPN. The concept of targeted therapy in MPN
may be more complicated than first thought. Other JAK inhibitors are
in various stages of investigation for the treatment of MF. These
include CYT387 which has demonstrated efficacy in reducing spleen
size as ruxolitinib did, but with the added benefit of decreasing anae-
mia [55]. Pacritinib (SB1518), a dual JAK2/Fms like tyrosine kinase 3
inhibitor, has also proved efficacious in reducing spleen size and con-
stitutional symptoms and is being trialled in patients with low baseline
platelet counts (PERSIST-1 and PERSIST-2) [56, 57]. A major advan-
tage of these trials against the ruxolitinib trials was that patients with
any degree of cytopenias were eligible. However, the US Food and
Drug Administration (FDA) placed a full clinical hold on pacritinib fol-
lowing reports of patient deaths related to cardiac failure and intracra-
nial haemorrhage. The full clinical data from these studies are under
review, and further dose finding studies may have to be performed.
Several other agents including fedratinib (SAR302503), CEP-701,
XL019, LY278544, BMS-911543 and AZD 1480 have been removed
from trials due to various complications including neurological toxici-
ties, myelosuppression or insufficient efficacy [40].
A variety of novel small molecule therapies are under investigation
in combination with JAK inhibitors. Given the landscape of epigenetic
mutations alongside JAK2 mutations, it is possible that drugs such as
histone deacetylase inhibitors (HDAC) like Givinostat [58, 59], telom-
erase inhibitors (imetelstat), or DNMT inhibitors could work synergis-
tically with JAK inhibitors. There is no question that hypomethylating
agents (azacytidine and decitabine) have offered clinical benefit to
selected MDS/AML patients [60]. Other targeted therapies include
PI3K (phosphoinositide 3-kinase) inhibitors or mammalian target of
rapamycin (mTOR) inhibitors which target enzymes which are part of
the PI3K/AKT/mTOR pathway [40]. There are many components
within this pathway and inhibition may result in tumour suppression.
A trial of a PI3K inhibitor used in combination with ruxolitinib showed
antiproliferative effects [61]. Despite recent advances, the true role of
Table 1 Mutations in epigenetic-associated genes and their current prognostic value in myeloid malignancies
Mutation Area of regulation MPN effect Significance in MDS/AML
JAK2 Histone modification Unknown No data, rare event in de novo AML
TET2 DNA methylation Poor risk, seen at leukaemic transformation No clear significance in MDS
Worse prognosis in normal karyotype AML
DNMT3A DNA methylation Unknown Adverse prognosis
IDH1/2 DNA methylation Poor risk at blast phase No clear importance
ASXL1 Histone modification Poor risk Poor risk
EZH2 Histone modification Unknown Adverse outcome in CMML and AML
SF3B1 miRNA regulation Unknown Good prognosis, seen commonly in MDS-RS
SRSF2 miRNA regulation Poor risk Worse prognosis, clustered in MDS with excess blasts
IKZF1 miRNA regulation Poor risk Unclear, possible link with AML Monosomy 7
JAK2, Janus kinase 2; TET2, Ten-eleven translocation 2; DNMT3A, DNA methyltransferase 3A; IDH1/2, Dehydrogenase 1/2; ASXL1, Addition of
sex combs like protein 1; EZH2, Enhancer of zeste homolog 2; SF3B1, Splicing factor 3 subunit 1; SRSF2, Serine and arginine splicing factor 2;
IFZF1, IKAROS family zinc finger 1; RS, Ring sideroblasts.
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molecular status in the choice of treatment of individual patients
requires further work before it can be applied routinely [40].
Conclusions
Mutations in MPN are involved in a wide range of cellular pathways
including cytokine receptor signalling but also the regulation of
gene expression [2]. Currently known MPN-associated mutations
include JAK2, MPL, LNK, CBL, CALR, TET2, ASXL1, IDH1, IDH2,
IKZF1 and EZH2 (Table 1: Mutations in epigenetic regulators and
their current prognostic value in myeloid malignancies) [36]. In
other myeloid malignancies, AML and myelodysplastic syndrome
(MDS), the number of mutations at diagnosis correlates with time
to leukaemic transformation. In these patients, molecularly guided
therapeutic trials have led to improved risk stratification and the
development of targeted therapy [6]. However, in MPN, certain
mutations may be present at disease initiation and others acquired
in a random fashion throughout the disease course. In addition,
some of these mutations are not mutually exclusive, making the
hierarchy complex and unpredictable. This makes it more difficult
to predict MPN patient outcomes at a single time-point [6]. More
than a decade on from the original description of JAK2 V617F, it
seems that contributing the MPN phenotype to constitutive activa-
tion of JAK2 is to over simplify the complex molecular interactions
that regulate the JAK/STAT pathway. Along with the recent descrip-
tion of the CALR mutation, differences in the epigenetic landscape
have been hypothesised to be a key component, with studies show-
ing aberrantly methylated genes in MPN patients particularly at
transformation to AML [36]. Other important insights into MPN
pathogenesis have appeared with TET2 seeming to be an important
driver of leukaemic transformation [62]. Enhancing our knowledge
about the mutation profile of patients may allow them to be strati-
fied into risk groups which would aid clinical decision making.
Management of MPN patients has now evolved and requires care-
fully consideration of individual patient disease burden, comorbidi-
ties and molecular status. JAK inhibitors have had a meaningful
impact as single agent therapy in PMF and now potentially resistant
cases of PV and ET. Ongoing work will answer whether the use of
epigenetic therapies as alterative pathways in combination with JAK
inhibitors may be more effective than single agent treatment.
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